ZA200908298B - Bicycloaniline derivative - Google Patents

Bicycloaniline derivative

Info

Publication number
ZA200908298B
ZA200908298B ZA200908298A ZA200908298A ZA200908298B ZA 200908298 B ZA200908298 B ZA 200908298B ZA 200908298 A ZA200908298 A ZA 200908298A ZA 200908298 A ZA200908298 A ZA 200908298A ZA 200908298 B ZA200908298 B ZA 200908298B
Authority
ZA
South Africa
Prior art keywords
bicycloaniline
derivative
bicycloaniline derivative
Prior art date
Application number
ZA200908298A
Other languages
English (en)
Inventor
Makoto Bamba
Hidetomo Furuyama
Kenji Niiyama
Toshihiro Sakamoto
Satoshi Sunami
Fuyuki Takahashi Keiji Yamamoto
Takashi Yoshizumi
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Publication of ZA200908298B publication Critical patent/ZA200908298B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200908298A 2007-06-15 2009-11-24 Bicycloaniline derivative ZA200908298B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007159217 2007-06-15

Publications (1)

Publication Number Publication Date
ZA200908298B true ZA200908298B (en) 2010-08-25

Family

ID=40129803

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200908298A ZA200908298B (en) 2007-06-15 2009-11-24 Bicycloaniline derivative

Country Status (22)

Country Link
US (1) US8436004B2 (pt)
EP (1) EP2168966B1 (pt)
JP (1) JP5129812B2 (pt)
KR (1) KR20100024932A (pt)
CN (1) CN101784551A (pt)
AU (1) AU2008262837B2 (pt)
CA (1) CA2689429C (pt)
CY (1) CY1118448T1 (pt)
DK (1) DK2168966T3 (pt)
ES (1) ES2608940T3 (pt)
HR (1) HRP20161536T1 (pt)
HU (1) HUE032403T2 (pt)
IL (1) IL202262A0 (pt)
LT (1) LT2168966T (pt)
MX (1) MX2009013728A (pt)
NZ (1) NZ581936A (pt)
PL (1) PL2168966T3 (pt)
PT (1) PT2168966T (pt)
RU (1) RU2010101052A (pt)
SI (1) SI2168966T1 (pt)
WO (1) WO2008153207A1 (pt)
ZA (1) ZA200908298B (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011516494A (ja) * 2008-04-07 2011-05-26 ギリアード サイエンシーズ, インコーポレイテッド ステアロイル−CoAデサチュラーゼの阻害剤として使用するための2H−ベンゾ[b][1,4]オキサジン−3(4H)−オン誘導体
EP2303885B1 (en) * 2008-06-12 2013-07-03 Merck Sharp & Dohme Corp. Process for producing bicycloaniline derivatives
CA2745970A1 (en) 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivative
CA2745959A1 (en) 2008-12-12 2010-06-17 Msd K.K. Dihydropyrimidopyrimidine derivatives
JP2012518598A (ja) * 2009-02-25 2012-08-16 Msd株式会社 ピリミドピリミドインダゾール誘導体
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
US8796289B2 (en) 2011-07-19 2014-08-05 Abbvie Inc. Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases
US9345705B2 (en) 2011-09-15 2016-05-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
PT3495367T (pt) 2012-06-13 2020-11-12 Incyte Holdings Corp Compostos tricíclicos substituídos como inibidores de fgfr
CN103113311A (zh) * 2012-07-19 2013-05-22 南京邮电大学 一类2-芳基喹唑啉或2-杂环芳基喹唑啉衍生物及其制备方法
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
ME02925B (me) * 2012-11-28 2018-04-20 Merck Sharp & Dohme Kompozicije i postupci za liječenje kancera
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
TWI647220B (zh) 2013-03-15 2019-01-11 美商西建卡爾有限責任公司 雜芳基化合物及其用途
AU2014228746B2 (en) 2013-03-15 2018-08-30 Celgene Car Llc Heteroaryl compounds and uses thereof
NZ711376A (en) 2013-03-15 2020-01-31 Sanofi Sa Heteroaryl compounds and uses thereof
TWI715901B (zh) 2013-04-19 2021-01-11 美商英塞特控股公司 作為fgfr抑制劑之雙環雜環
GB201322602D0 (en) 2013-12-19 2014-02-05 Almac Discovery Ltd Pharmaceutical compounds
CN104725333A (zh) * 2013-12-20 2015-06-24 北京蓝贝望生物医药科技股份有限公司 一种新的氮杂环庚烷衍生物的制备方法
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CN113004278B (zh) 2015-02-20 2023-07-21 因赛特控股公司 作为fgfr抑制剂的双环杂环
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
WO2017031116A1 (en) * 2015-08-18 2017-02-23 The Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of ku70/80 and uses thereof
WO2017091473A1 (en) * 2015-11-24 2017-06-01 Indiana University Research & Technology Corporation Composition for blocking angiogenesis
UA123032C2 (uk) 2016-12-20 2021-02-03 Астразенека Аб Амінотриазолопіридинові сполуки та їхнє застосування у лікуванні раку
CA3058457A1 (en) 2017-03-31 2018-10-04 Seattle Genetics, Inc. Combinations of chk1- and wee1 - inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
AU2018347307A1 (en) * 2017-10-09 2020-04-23 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
US11299493B2 (en) 2017-10-09 2022-04-12 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
CN109810111B (zh) * 2017-11-20 2023-10-27 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
WO2019213544A2 (en) 2018-05-04 2019-11-07 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
CR20200591A (es) 2018-05-04 2021-03-31 Incyte Corp Sales de un inhibidor de fgfr
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
US20220162229A1 (en) * 2019-04-09 2022-05-26 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
WO2020210375A1 (en) 2019-04-09 2020-10-15 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
WO2020210383A1 (en) * 2019-04-09 2020-10-15 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN112442049A (zh) * 2019-09-03 2021-03-05 微境生物医药科技(上海)有限公司 作为Wee1抑制剂的嘧啶衍生物
TW202128685A (zh) 2019-10-14 2021-08-01 美商英塞特公司 作為fgfr抑制劑之雙環雜環
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3158274A1 (en) 2019-10-25 2021-04-29 Astrazeneca Ab Methods of treating cancer
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2022174765A1 (zh) * 2021-02-19 2022-08-25 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的稠环化合物
IL307863A (en) 2021-04-29 2023-12-01 Novartis Ag Diubiquitinase-directed chimeras and related methods
MX2023012491A (es) * 2021-04-30 2023-11-03 Wigen Biomedicine Tech Shanghai Co Ltd Compuesto ciclico condensado como inhibidor de wee-1, metodo para su preparacion y uso de este.
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2023170065A1 (en) 2022-03-07 2023-09-14 Debiopharm International S.A. Methods of treating small cell lung cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU763839B2 (en) * 1998-05-26 2003-07-31 Warner-Lambert Company Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
WO2001070741A1 (en) 2000-03-06 2001-09-27 Warner-Lambert Company 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
US7196090B2 (en) * 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
TW200413381A (en) 2002-11-04 2004-08-01 Hoffmann La Roche Novel amino-substituted dihydropyrimido [4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents
AU2003292024A1 (en) * 2002-11-15 2004-06-15 Basf Aktiengesellschaft Fungicidal mixtures for controlling rice pathogens
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
TW200530235A (en) * 2003-12-24 2005-09-16 Renovis Inc Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
RU2346996C2 (ru) 2004-06-29 2009-02-20 ЮРОПИЭН НИКЕЛЬ ПиЭлСи Усовершенствованное выщелачивание основных металлов
FR2873118B1 (fr) * 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
WO2006032452A1 (en) 2004-09-21 2006-03-30 F. Hoffmann-La Roche Ag 6-(2-alkyl-phenyl) - pyrido[2,3-d] pyrimidines useful as proteine kinase inhibitors
DE602006020138D1 (de) 2005-06-29 2011-03-31 Compumedics Ltd Sensoranordnung mit leitfähiger brücke
CA2652648C (en) 2006-02-14 2016-10-25 Vertex Pharmaceuticals Incorporated Dihydrodiazepines useful as inhibitors of protein kinases

Also Published As

Publication number Publication date
AU2008262837A1 (en) 2008-12-18
SI2168966T1 (sl) 2017-03-31
CA2689429C (en) 2012-08-21
JP5129812B2 (ja) 2013-01-30
RU2010101052A (ru) 2011-07-20
LT2168966T (lt) 2017-01-10
HUE032403T2 (en) 2017-09-28
EP2168966A1 (en) 2010-03-31
NZ581936A (en) 2011-08-26
CN101784551A (zh) 2010-07-21
JPWO2008153207A1 (ja) 2010-08-26
IL202262A0 (en) 2010-06-16
ES2608940T3 (es) 2017-04-17
HRP20161536T1 (hr) 2016-12-30
PT2168966T (pt) 2017-01-02
CY1118448T1 (el) 2017-06-28
WO2008153207A1 (ja) 2008-12-18
EP2168966B1 (en) 2016-09-28
PL2168966T3 (pl) 2017-06-30
CA2689429A1 (en) 2008-12-18
MX2009013728A (es) 2010-01-25
US8436004B2 (en) 2013-05-07
US20110135601A1 (en) 2011-06-09
KR20100024932A (ko) 2010-03-08
AU2008262837B2 (en) 2013-05-23
EP2168966A4 (en) 2011-02-16
DK2168966T3 (en) 2017-01-23

Similar Documents

Publication Publication Date Title
EP2226315A4 (en) 2-AMINOQUINAZOLINE DERIVATIVE
ZA200908298B (en) Bicycloaniline derivative
EP2213673A4 (en) PYRIDONE-SUBSTITUTED DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE
HK1149756A1 (en) Isoxazolo-pyridine derivatives
IL205753A0 (en) Isoxazolo-pyridazine derivatives
EP2120569A4 (en) SPIROCHROMANONDERIVATE
IL202020A0 (en) Spiroindolinone derivatives
ZA201001058B (en) Quinazolinamide derivatives
ZA201000431B (en) Indazolamide derivatives
IL205755A0 (en) Isoxazolo-pyrazine derivatives
IL200618A0 (en) Aza-pyridopyrimidinone derivatives
EP2241567A4 (en) Bicycloamine DERIVATIVE
HK1144196A1 (en) 4-pyrimidinesulfamide derivative 4-
IL202667A0 (en) Isoxazole-imidazole derivatives
PL2245028T3 (pl) Pochodne 5-aminocyklilometyloksazolidyn-2-onu
EP2133347A4 (en) 1-BIARYLAZETIDINONDERIVATE
EP2163554A4 (en) PYRIMIDODIAZEPINONE DERIVATIVE
HK1141009A1 (en) Sulfonyl-quinoline derivatives
IL202159A0 (en) Piperidine-amide derivatives
EP2157084A4 (en) 5-phenyl-3-pyridazinone derivative
EP2248811A4 (en) 2-OXOCHROMENE DERIVATIVE
EP2228362A4 (en) 4-HYDROXYPHENYLALKYLAMINE DERIVATIVE
HK1146276A1 (en) Thiadiazinone derivatives
EP2204368A4 (en) 4-SULFONYLPIPERIDINE DERIVATIVES
ZA201000311B (en) Sulfonyl-quinoline derivatives